Literature DB >> 11565136

Primary prophylaxis of variceal hemorrhage.

R C Lowe1, N D Grace.   

Abstract

Figure 3 shows an algorithm for the primary prevention of variceal hemorrhage. Pharmacologic therapy is the current standard of treatment for the primary prophylaxis of esophageal variceal bleeding. Patients with medium or large varices should be treated with a nonselective beta-blocker with the dose titrated to achieve a 25% decrement in resting heart rate or a heart rate of 55 to 60 bpm. The development of symptoms will, of course, limit the dose used. As discussed previously, these therapeutic endpoints are not well correlated with decreases in portal pressure. Measurement of the HVPG before therapy and after 3 months of therapy provides a rational approach to drug dosing. If the HVPG decreases by 20% or to less than 12 mm Hg, the medication dose will be effective in preventing hemorrhage. If, however, the HVPG is not appropriately lowered, a long-acting nitrate may be added. Patients with small varices should be observed, with endoscopic examinations every 2 years to assess progression of variceal size. Endoscopic therapy is not indicated for the primary prevention of variceal bleeding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565136     DOI: 10.1016/s1089-3261(05)70187-2

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist.

Authors:  R Todd Stravitz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-05

2.  Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients.

Authors:  Christoph Elsing; Sabine Harenberg; Wolfgang Stremmel; Thomas Herrmann
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

3.  Practice patterns in screening for varices: an American survey.

Authors:  A S Barritt; M R Arguedas
Journal:  Dig Liver Dis       Date:  2009-02-28       Impact factor: 4.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.